Supernus: Sales Stretching Higher, But Not Reflected In Economic Leverage (NASDAQ:SUPN)

ozgurdonmaz Investment Briefing Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a biopharmaceutical company that specializes in developing and commercializing treatments for central nervous system (“CNS”) disorders. The company’s neuroscience portfolio comprises a range of approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (“ADHD”), and hypomobility in Parkinson’s Disease (“PD”). It currently has 8 commercial products in the…

Read More

Privia Health: Unit Economics Stretching Higher At Qualified Growth Rates, Buy (PRVA)

aluxum Investment briefing After extensively reviewing the investment case for Privia Health Group, Inc. (NASDAQ:PRVA) findings corroborate a revised buy rating in my view. Following the September FY’22 publication on PRVA, several pointers suggest the company can unlock risk capital for equity investors this year. PRVA exhibits growth in key business metrics underlying its unit…

Read More